SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Conditions
- Acute Myeloid LeukemiaBlastic Plasmacytoid Dendritic Cell NeoplasmMyelodysplastic Syndrome
- Interventions
- First Posted Date
- 2017-04-13
- Last Posted Date
- 2025-06-19
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 72
- Registration Number
- NCT03113643
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2017-03-06
- Last Posted Date
- 2020-05-22
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 37
- Registration Number
- NCT03071276
- Locations
- 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
- Conditions
- Acute Myeloid Leukemia (AML)FMS-like Tyrosine Kinase-3 (FLT3) Mutations
- First Posted Date
- 2017-03-03
- Last Posted Date
- 2021-04-20
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Registration Number
- NCT03070093
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸Rocky Mountain Cancer Center-M, Aurora, Colorado, United States
🇺🇸Memorial Healthcare System, Pembroke Pines, Florida, United States
A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2017-03-03
- Last Posted Date
- 2025-08-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 211
- Registration Number
- NCT03069352
- Locations
- 🇺🇸
H. Lee Moffit Cancer Center /ID# 164273, Tampa, Florida, United States
🇺🇸Norton Cancer Institute /ID# 158998, Louisville, Kentucky, United States
🇺🇸Univ of Pittsburgh Med Ctr /ID# 158997, Pittsburgh, Pennsylvania, United States
Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart Review
- Conditions
- Acute Myeloid Leukemia (AML)
- First Posted Date
- 2017-02-08
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 1027
- Registration Number
- NCT03047083
- Locations
- 🇺🇸
Sermo, Charlotte, North Carolina, United States
A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)
- Conditions
- Leukemia, Myeloid, AcuteMyelodysplastic Syndromes
- Interventions
- Drug: AZA
- First Posted Date
- 2017-01-25
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- OncoVerity, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT03030612
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
- First Posted Date
- 2016-12-19
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 356
- Registration Number
- NCT02997202
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Virginia G Piper Cancer Center, Scottsdale, Arizona, United States
A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2016-12-15
- Last Posted Date
- 2025-08-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 443
- Registration Number
- NCT02993523
- Locations
- 🇺🇸
City of Hope /ID# 154105, Duarte, California, United States
🇺🇸University of California, Los Angeles /ID# 154107, Los Angeles, California, United States
🇺🇸University of California, Davis Comprehensive Cancer Center /ID# 162725, Sacramento, California, United States
Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPY
- Conditions
- Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)
- Interventions
- Procedure: Bone marrow analyses and CBC with differentialOther: Flow cytometry analysesOther: Central biobankingProcedure: Histopathology analysisGenetic: Cytogenetic analysisProcedure: Serum chemistryProcedure: Automated CBCProcedure: Pregnancy Test
- First Posted Date
- 2016-12-14
- Last Posted Date
- 2018-10-25
- Lead Sponsor
- GWT-TUD GmbH
- Target Recruit Count
- 25
- Registration Number
- NCT02992860
- Locations
- 🇫🇷
CHU Nantes, Nantes, France
🇫🇷Hospital Archet 1, Nice, France
🇫🇷Hospital Saint Louis, Paris, France
Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation
- First Posted Date
- 2016-12-07
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 37
- Registration Number
- NCT02984995